Trial · NCT03050619
Characteristics of Empagliflozin Initiators
NCT03050619, Completed, Boehringer Ingelheim; results first posted 2019-01-25
3 sourcestrials-2026-11-12-0.5.0
Download JSON
Cite this record
ConductScience Library. Characteristics of Empagliflozin Initiators. Trials, record NCT03050619. Release trials-2026-11-12-0.5.0, 12 Nov 2026. https://conductscience.org/library/trials/NCT03050619
On this page
Trial
As registered on ClinicalTrials.gov, in the graph's capture of the registry.
- Title
- Characteristics of Empagliflozin Initiators
- NCT number
- NCT03050619
- Status
- Completed
- Enrollment
- 31,908 participants, actual
- Lead sponsor
- Boehringer Ingelheim
- Conditions
- Type 2 Diabetes
- Interventions
- Empagliflozin, Other SGLT2 inhibitors, Other non-insulin GLDs
- First posted
- 2017-02-13
- Last updated
- 2019-01-25
- Results first posted
- 2019-01-25
- Limitations and caveats
- The utilization of empagliflozin in the first year after launch was not as high as other exposure categories.
Source ClinicalTrials.gov
Registered outcomes21
Each outcome the trial registered, primary first, in ClinicalTrials.gov's words.
| List | Outcome | Time frame | Description |
|---|---|---|---|
| Primary | Baseline Characteristics of Adults (as Measured by Demographics) With a Recorded Diagnosis of T2DM Starting Index Prescriptions in the UK | Baseline | Baseline characteristics of adults (as measured by demographics) with a recorded diagnosis of T2DM who initiated index prescriptions (empagliflozin, other SGLT-2i or other commonly used non-insulin GLDs (comprising DPP-4i, metformin, SU and GLP-1 agonists)) are presented. |
| Primary | Baseline Characteristics of Adults (as Measured by Life Style Factors (Smoking and Alcohol Use)) With a Recorded Diagnosis of T2DM Starting Index Prescriptions in the UK | Baseline | Baseline characteristics of adults (as measured by life style factors (smoking and alcohol use)) with a recorded diagnosis of T2DM who initiated index prescriptions (empagliflozin, other SGLT-2i or other commonly used non-insulin GLDs (comprising DPP-4i, metformin, SU and GLP-1 agonists)) are presented. NA= NR (Not Reported) (variables for which patient counts were \<5) |
| Primary | Baseline Characteristics of Adults (as Measured by Life Style Factors (BMI)) With a Recorded Diagnosis of T2DM Starting Index Prescriptions in the UK | Baseline | Baseline characteristics of adults (as measured by life style factors (BMI)) with a recorded diagnosis of T2DM who initiated index prescriptions (empagliflozin, other SGLT-2i or other commonly used non-insulin GLDs (comprising DPP-4i, metformin, SU and GLP-1 agonists)) is presented. Mean and standard deviation (SD) of body mass index (BMI) measured is presented along with number of subjects with available data. |
| Primary | Baseline Characteristics of Adults (as Measured by Life Style Factors (Blood Pressure)) With a Recorded Diagnosis of T2DM Starting Index Prescriptions in the UK | Baseline | Baseline characteristics of adults (as measured by life style factors (blood pressure)) with a recorded diagnosis of T2DM who initiated index prescriptions (empagliflozin, other SGLT-2i or other commonly used non-insulin GLDs (comprising DPP-4i, metformin, SU and GLP-1 agonists)) is presented. Mean and standard deviation (SD) of Systolic blood pressure (SBP) and Diastolic blood pressure (DBP) measured is presented along with number of subjects with available data. |
| Primary | Baseline Characteristics of Adults (as Measured by Glycated Haemoglobin (HbA1c)) With a Recorded Diagnosis of T2DM Starting Index Prescriptions in the UK | Baseline | Baseline characteristics of adults (as measured by glycated haemoglobin (HbA1c)) with a recorded diagnosis of T2DM who initiated index prescriptions (empagliflozin, other SGLT-2i or other commonly used non-insulin GLDs (comprising DPP-4i, metformin, SU and GLP-1 agonists)) is presented. Mean and standard deviation (SD) of glycated haemoglobin (HbA1c) measured is presented along with number of subjects with available data. |
| Primary | Baseline Characteristics of Adults (as Measured by Laboratory Tests) With a Recorded Diagnosis of T2DM Starting Index Prescriptions in the UK | Baseline | Baseline characteristics of adults (as measured by laboratory tests) with a recorded diagnosis of T2DM who initiated index prescriptions (empagliflozin, other SGLT-2i or other commonly used non-insulin GLDs (comprising DPP-4i, metformin, SU and GLP-1 agonists)) are presented. Mean and standard deviation (SD) of total cholesterol (TC), high-density lipoproteins level (HDL), Low-density lipoprotein level (LDL) and triglyceride level (TG) measured are presented along with number of subjects with available data. |
| Primary | Baseline Characteristics of Adults (as Measured by Estimated Glomerular Filtration Rate (eGFR)) With a Recorded Diagnosis of T2DM Starting Index Prescriptions in the UK | Baseline | Baseline characteristics of adults (as measured by estimated glomerular filtration rate (eGFR)) with a recorded diagnosis of T2DM who initiated index prescriptions (empagliflozin, other SGLT-2i or other commonly used non-insulin GLDs (comprising DPP-4i, metformin, SU and GLP-1 agonists)) is presented. Mean and standard deviation (SD) of estimated glomerular filtration rate (eGFR) measured is presented along with number of subjects with available data. |
| Primary | Baseline Characteristics of Adults (as Measured by Creatinine Serum (SCR)) With a Recorded Diagnosis of T2DM Starting Index Prescriptions in the UK | Baseline | Baseline characteristics of adults (as measured by by creatinine serum (SCR)) with a recorded diagnosis of T2DM who initiated index prescriptions (empagliflozin, other SGLT-2i or other commonly used non-insulin GLDs (comprising DPP-4i, metformin, SU and GLP-1 agonists)) is presented. Mean and standard deviation (SD) of creatinine serum (SCR) measured is presented along with number of subjects with available data. |
| Primary | Baseline Characteristics of Adults (as Measured by Comorbidities) With a Recorded Diagnosis of T2DM Starting Index Prescriptions in the UK | Baseline | Baseline characteristics of adults (as measured by comorbidities) with a recorded diagnosis of T2DM who initiated index prescriptions (empagliflozin, other SGLT-2i or other commonly used non-insulin GLDs (comprising DPP-4i, metformin, SU and GLP-1 agonists)) are presented. |
| Primary | Baseline Characteristics of Adults (as Measured by Concomitant Medications) With a Recorded Diagnosis of T2DM Starting Index Prescriptions in the UK | Baseline | Baseline characteristics of adults (as measured by concomitant medications) with a recorded diagnosis of T2DM who initiated index prescriptions (empagliflozin, other SGLT-2i or other commonly used non-insulin GLDs (comprising DPP-4i, metformin, SU and GLP-1 agonists)) are presented. Subjects taking medication up to 60 days before index date are presented. |
1 to 10 of 21Source ClinicalTrials.gov
See all 21 registered outcomesOutcomes21
Each outcome the trial posted results for, in ClinicalTrials.gov's words.
| Type | Outcome | Time frame | Population | Units | Measured as |
|---|---|---|---|---|---|
| PRIMARY | Baseline Characteristics of Adults (as Measured by Demographics) With a Recorded Diagnosis of T2DM Starting Index Prescriptions in the UK | Baseline | All patients (older than 18 years), with a recorded T2DM, who initiated treatment with empagliflozin, other SGLT-2i, or other commonly used non-insulin GLDs (comprising DPP-4i, metformin, SU and GLP-1 agonists) between 01 August 2014 and 01 September 2015 were included. | Percentage of Participants | NUMBER |
| PRIMARY | Baseline Characteristics of Adults (as Measured by Life Style Factors (Smoking and Alcohol Use)) With a Recorded Diagnosis of T2DM Starting Index Prescriptions in the UK | Baseline | All patients (older than 18 years), with a recorded T2DM, who initiated treatment with empagliflozin, other SGLT-2i, or other commonly used non-insulin GLDs (comprising DPP-4i, metformin, SU and GLP-1 agonists) between 01 August 2014 and 01 September 2015 were included. | Percentage of Participants | NUMBER |
| PRIMARY | Baseline Characteristics of Adults (as Measured by Life Style Factors (BMI)) With a Recorded Diagnosis of T2DM Starting Index Prescriptions in the UK | Baseline | All patients (older than 18 years), with a recorded T2DM, who initiated treatment with empagliflozin, other SGLT-2i, or other commonly used non-insulin GLDs (comprising DPP-4i, metformin, SU and GLP-1 agonists) between 01 August 2014 and 01 September 2015 were included. | Kilogram per square meter (kg/m2) | MEAN |
| PRIMARY | Baseline Characteristics of Adults (as Measured by Life Style Factors (Blood Pressure)) With a Recorded Diagnosis of T2DM Starting Index Prescriptions in the UK | Baseline | All patients (older than 18 years), with a recorded T2DM, who initiated treatment with empagliflozin, other SGLT-2i, or other commonly used non-insulin GLDs (comprising DPP-4i, metformin, SU and GLP-1 agonists) between 01 August 2014 and 01 September 2015 were included. | Millimeter of mercury (mmHg) | MEAN |
| PRIMARY | Baseline Characteristics of Adults (as Measured by Glycated Haemoglobin (HbA1c)) With a Recorded Diagnosis of T2DM Starting Index Prescriptions in the UK | Baseline | All patients (older than 18 years), with a recorded T2DM, who initiated treatment with empagliflozin, other SGLT-2i, or other commonly used non-insulin GLDs (comprising DPP-4i, metformin, SU and GLP-1 agonists) between 01 August 2014 and 01 September 2015 were included. | Millimole per mole (mmol/mol) | MEAN |
| PRIMARY | Baseline Characteristics of Adults (as Measured by Laboratory Tests) With a Recorded Diagnosis of T2DM Starting Index Prescriptions in the UK | Baseline | All patients (older than 18 years), with a recorded T2DM, who initiated treatment with empagliflozin, other SGLT-2i, or other commonly used non-insulin GLDs (comprising DPP-4i, metformin, SU and GLP-1 agonists) between 01 August 2014 and 01 September 2015 were included. | Millimole per liter (mmol/L) | MEAN |
| PRIMARY | Baseline Characteristics of Adults (as Measured by Estimated Glomerular Filtration Rate (eGFR)) With a Recorded Diagnosis of T2DM Starting Index Prescriptions in the UK | Baseline | All patients (older than 18 years), with a recorded T2DM, who initiated treatment with empagliflozin, other SGLT-2i, or other commonly used non-insulin GLDs (comprising DPP-4i, metformin, SU and GLP-1 agonists) between 01 August 2014 and 01 September 2015 were included. | Milliliters per minute (ml/min) | MEAN |
| PRIMARY | Baseline Characteristics of Adults (as Measured by Creatinine Serum (SCR)) With a Recorded Diagnosis of T2DM Starting Index Prescriptions in the UK | Baseline | All patients (older than 18 years), with a recorded T2DM, who initiated treatment with empagliflozin, other SGLT-2i, or other commonly used non-insulin GLDs (comprising DPP-4i, metformin, SU and GLP-1 agonists) between 01 August 2014 and 01 September 2015 were included. | Micromoles per liter (umol/L) | MEAN |
| PRIMARY | Baseline Characteristics of Adults (as Measured by Comorbidities) With a Recorded Diagnosis of T2DM Starting Index Prescriptions in the UK | Baseline | All patients (older than 18 years), with a recorded T2DM, who initiated treatment with empagliflozin, other SGLT-2i, or other commonly used non-insulin GLDs (comprising DPP-4i, metformin, SU and GLP-1 agonists) between 01 August 2014 and 01 September 2015 were included. | Percentage of Participants | NUMBER |
| PRIMARY | Baseline Characteristics of Adults (as Measured by Concomitant Medications) With a Recorded Diagnosis of T2DM Starting Index Prescriptions in the UK | Baseline | All patients (older than 18 years), with a recorded T2DM, who initiated treatment with empagliflozin, other SGLT-2i, or other commonly used non-insulin GLDs (comprising DPP-4i, metformin, SU and GLP-1 agonists) between 01 August 2014 and 01 September 2015 were included. | Percentage of Participants | NUMBER |
1 to 10 of 21Source ClinicalTrials.gov
See all 21 outcomesResults by group630
Each measurement the trial posted, group by group, in the words and numbers it posted.
| Outcome | Group | Category | Value | Spread | Units |
|---|---|---|---|---|---|
| Baseline Characteristics of Adults (as Measured by Demographics) With a Recorded Diagnosis of T2DM Starting Index Prescriptions in the UK | Empagliflozin | Age (18 - 35 years) | 5.45 | Percentage of Participants | |
| Baseline Characteristics of Adults (as Measured by Demographics) With a Recorded Diagnosis of T2DM Starting Index Prescriptions in the UK | Other SGLT-2i | Age (18 - 35 years) | 1.76 | Percentage of Participants | |
| Baseline Characteristics of Adults (as Measured by Demographics) With a Recorded Diagnosis of T2DM Starting Index Prescriptions in the UK | Dipeptidyl Peptidase-4 Inhibitors (DPP-4i) | Age (18 - 35 years) | 1.44 | Percentage of Participants | |
| Baseline Characteristics of Adults (as Measured by Demographics) With a Recorded Diagnosis of T2DM Starting Index Prescriptions in the UK | Metformin | Age (18 - 35 years) | 3.03 | Percentage of Participants | |
| Baseline Characteristics of Adults (as Measured by Demographics) With a Recorded Diagnosis of T2DM Starting Index Prescriptions in the UK | Sulfonylureas (SU) | Age (18 - 35 years) | 2.68 | Percentage of Participants | |
| Baseline Characteristics of Adults (as Measured by Demographics) With a Recorded Diagnosis of T2DM Starting Index Prescriptions in the UK | Glucagon-like Peptide-1 (GLP-1) Agonists | Age (18 - 35 years) | 3.20 | Percentage of Participants | |
| Baseline Characteristics of Adults (as Measured by Demographics) With a Recorded Diagnosis of T2DM Starting Index Prescriptions in the UK | Empagliflozin | Age (36 - 49 years) | 22.73 | Percentage of Participants | |
| Baseline Characteristics of Adults (as Measured by Demographics) With a Recorded Diagnosis of T2DM Starting Index Prescriptions in the UK | Other SGLT-2i | Age (36 - 49 years) | 18.70 | Percentage of Participants | |
| Baseline Characteristics of Adults (as Measured by Demographics) With a Recorded Diagnosis of T2DM Starting Index Prescriptions in the UK | Dipeptidyl Peptidase-4 Inhibitors (DPP-4i) | Age (36 - 49 years) | 11.45 | Percentage of Participants | |
| Baseline Characteristics of Adults (as Measured by Demographics) With a Recorded Diagnosis of T2DM Starting Index Prescriptions in the UK | Metformin | Age (36 - 49 years) | 16.86 | Percentage of Participants |
1 to 10 of 630Source ClinicalTrials.gov
See all 630 results by groupParticipant flow18
How many started, completed or left each group, period by period.
| Period | Milestone | Group | Participants | Units counted |
|---|---|---|---|---|
| Overall Study | STARTED | Empagliflozin | 129 | |
| Overall Study | STARTED | Other SGLT-2i | 3,926 | |
| Overall Study | STARTED | Dipeptidyl Peptidase-4 Inhibitors (DPP-4i) | 6,416 | |
| Overall Study | STARTED | Metformin | 14,007 | |
| Overall Study | STARTED | Sulfonylureas (SU) | 6,079 | |
| Overall Study | STARTED | Glucagon-like Peptide-1 (GLP-1) Agonists | 1,351 | |
| Overall Study | COMPLETED | Empagliflozin | 129 | |
| Overall Study | COMPLETED | Other SGLT-2i | 3,926 | |
| Overall Study | COMPLETED | Dipeptidyl Peptidase-4 Inhibitors (DPP-4i) | 6,416 | |
| Overall Study | COMPLETED | Metformin | 14,007 |
1 to 10 of 18Source ClinicalTrials.gov
See all 18 participant flowAdverse events0
Each adverse event the trial posted, group by group: the participants affected out of those at risk.
None in this release.
Adverse event totals18
The totals the trial posted for each group.
| Total | Group | Affected | At risk |
|---|---|---|---|
| Total, all-cause mortality | Empagliflozin | ||
| Total, all-cause mortality | Other SGLT-2i | ||
| Total, all-cause mortality | Dipeptidyl Peptidase-4 Inhibitors (DPP-4i) | ||
| Total, all-cause mortality | Metformin | ||
| Total, all-cause mortality | Sulfonylureas (SU) | ||
| Total, all-cause mortality | Glucagon-like Peptide-1 (GLP-1) Agonists | ||
| Total, other adverse events | Empagliflozin | 0 | 0 |
| Total, other adverse events | Other SGLT-2i | 0 | 0 |
| Total, other adverse events | Dipeptidyl Peptidase-4 Inhibitors (DPP-4i) | 0 | 0 |
| Total, other adverse events | Metformin | 0 | 0 |
1 to 10 of 18Source ClinicalTrials.gov
See all 18 adverse event totalsPapers0
The papers the trial lists on ClinicalTrials.gov.
None in this release.
Grants0
The grants NIH RePORTER links to the trial, newest funded first: NIH's, and some of AHRQ's, CDC's, FDA's and VA's. Each shows its title, principal investigators, organization and funder in its newest year.
None in this release.
Trial comparisons0
Comparisons of the trial's two groups, calculated by ConductScience from the counts it posted.
None in this release.
Tests0
The ConductCognition tests this trial's registered outcomes name, as ScienceGraph matched them in trial-tests-2026-11-12-0.2.1.
None in this release.
Data dates
The day each source was copied for this release.
Sources 3
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ClinicalTrials.govNo license stated
- NIH RePORTER's clinical studies and project filesPublic domain
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ClinicalTrials.govnone stated
- NIH RePORTER's clinical studies and project filesPublic domain (NIH RePORTER)
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this trial from software.
The record and each of its lists are JSON, twenty rows a page. No key.
GET https://conductscience.org/api/trials/v1/NCT03050619
GET https://conductscience.org/api/trials/v1/NCT03050619/registered?page=2